AMAG snaps up rights to new med Intrarosa to compete with Pfizer’s Premarin® vaginal cream

Tracy Staton reporting for FiercePharma.com writes as follows.   AMAG Pharmaceuticals has big ambitions for its women’s health business, so it’s snapped up the rights to a new med, Intrarosa, to beef up that portfolio. The company plans to tout Intrarosa’s safety profile to set it apart from established estrogen-based treatments such as Pfizer’s Premarin cream…